Zejula® (niraparib) – Updated indication
June 18, 2025 - The FDA approved an update to the label for GSK’s Zejula (niraparib), to narrow the indication for maintenance treatment of adult patients with advanced ovarian cancer in the first line setting to those with homologous recombination deficiency (HRD)-positive tumors only.
Top